Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06785402 · ClinicalTrials.gov registry record · Phase 1
Ceftriaxone for Post-Treatment Lyme Disease
A Phase 1 study of Post-treatment Lyme Disease Syndrome, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06785402 is a Phase 1 study of Post-treatment Lyme Disease Syndrome that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06785402, a Phase 1 study of Post-treatment Lyme Disease Syndrome, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS). The goal of this study is to investigate if giving Ceftriaxone every 5 days for about 6 weeks kills the organism that produces persistent Lyme infection. Enrolled participants will be randomized 1:1 receiving either pulse-dosed ceftriaxone or placebo \[dextrose (5% in water), (D5W)\], intravenously. Participants will be evaluated at each of the study visits, and then in a follow-up phase out to 12 months. They will be unblinded at 6 months and those randomized to the placebo group will be offered pulse-dosed ceftriaxone on the same schedule as those randomized to the drug group. All patients will be followed up for a total of 12 months post treatment initiation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ceftriaxone treatment
Study Locations (1)
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-15 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06785402
The ClinicalTrials.gov registry entry for NCT06785402 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-treatment Lyme Disease Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06785402 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06785402 about?
NCT06785402 is a clinical study titled "Ceftriaxone for Post-Treatment Lyme Disease". Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS). The goal of this study is to investigate if giving Ceftriaxone every 5 days for about 6 weeks kil...
What is the current status of trial NCT06785402?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-15. Estimated completion is 2027-12-01.
What conditions does trial NCT06785402 study?
This clinical trial studies the following conditions: Post-treatment Lyme Disease Syndrome.
What interventions are being tested in trial NCT06785402?
The interventions under investigation include: Placebo (DRUG), Ceftriaxone treatment (DRUG).
Who is sponsoring clinical trial NCT06785402?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06785402 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post-treatment Lyme Disease Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.